Cervical Cancer Awareness 2026

Committed to strengthening Cervical Cancer Awareness through better diagnostics.

Every two minutes, a woman loses her life to cervical cancer — a disease that is preventable, yet persistent. Its burden continues not only due to lack of awareness, but also because millions still face unequal access to HPV vaccination, regular screening, and timely treatment. Despite being both preventable and treatable, cervical cancer remains the 4th most common cancer among women worldwide.

Cervical cancer is primarily caused by persistent infection with high-risk HPV types. Factors that increase the risk include early sexual activity, multiple partners, smoking, weakened immunity, multiple pregnancies, and long-term use of oral contraceptives. Most importantly, lack of regular screening and low HPV vaccination coverage allow precancerous changes to go undetected leading to preventable cases progressing into cancer.

Immunohistochemistry (IHC) plays a crucial role in accurately diagnosing cervical pre-cancer and cancer, especially when routine cytology or biopsy findings are unclear.

• HPV16 helps identify one of the most oncogenic viral subtypes responsible for a major share of cervical cancers. Read More: https://bit.ly/DBS-HPV16

• p16 is widely used as the gold-standard surrogate marker for high-risk HPV–driven transformation, showing strong block positivity in High-Grade Squamous Intraepithelial Lesion (HSIL) and invasive carcinoma. Read More: https://dbiosys.com/product/p16/

• Ki-67 complements p16 by highlighting abnormal cell proliferation and helping distinguish low-grade from high-grade lesions. Read More: https://dbiosys.com/product/ki-67/

As we advance in awareness, screening, and diagnostic precision, our collective goal remains clear – delivering early, accurate diagnoses that empower timely treatment and better outcomes. Early detection opens the door to better care, and precision diagnostics lead the way.